Scientists Have Discovered A New Method Of Detecting Cancer.
A unexplored study marketed as an alternative to a mammogram for breast cancer detection is not an impressive screening TOOL, US health officials say. With the nipple aspirate test, a bust pump collects fluid from a woman's nipple. The fluid is then examined for eccentric and potentially cancerous cells. The test is advertised as easier, more comfortable and less painful than mammograms.
However, there is no ammunition to support claims that the test can detect breast cancer, said Dr David Lerner, a medical official at the US Food and Drug Administration and a breast imaging specialist. "FDA's trouble is that the nipple aspirate test is being touted as a standalone tool to screen for and distinguish breast cancer as an alternative to mammography," Lerner said in an agency news release.
So "Our horror is that women will forgo a mammogram and have this test instead". Skipping a mammogram could put a woman's constitution and life at risk if breast cancer goes undetected, Lerner warned. He said there is no detailed evidence that the nipple aspirate test, when used on its own, is an effective screening tool for knocker cancer or any other medical condition.
Showing posts with label breast. Show all posts
Showing posts with label breast. Show all posts
Sunday 16 February 2020
Saturday 18 January 2020
Docosahexaenoic Acid (DHA) Supplements For Breast-Feeding Mothers Is Good For Premature Infants
Docosahexaenoic Acid (DHA) Supplements For Breast-Feeding Mothers Is Good For Premature Infants.
Very too early infants have higher levels of DHA - an omega-3 fatty acid that's basic to the improvement and development of the brain - when their breast-feeding mothers believe DHA supplements, Canadian researchers have found. Researchers say a deficiency in DHA (docosahexaenoic acid) is common in very preterm infants, possibly because the ordinary diets of many in the or breast-feeding women lack the essential fatty acid, which is found in cold water fatty fish and fish lubricator supplements.
The study included breast-feeding mothers of 12 infants born at 29 weeks gestation or earlier. The mothers were given high-priced doses of DHA supplements until 36 weeks after conception. The mothers and babies in this intervention series were compared at date 49 to a control group of mothers of very preterm infants who didn't take DHA supplements.
The levels of DHA in the knocker milk of mothers who took DHA supplements were nearly 12 times higher than in the draw off of mothers in the control group. Infants in the intervention group received about seven times more DHA than those in the hold back group. Plasma DHA concentrations in mothers and babies in the intervention league were two to three times higher than those in the control group.
So "Our study has shown that supplementing mothers is a usable and effective way of providing DHA to low birthweight premature infants," review author Dr Isabelle Marc, an assistant professor in the pediatrics department at Laval University in Quebec, said in a item release. The DHA content in the breast drain of mothers who don't consume fish during the breast-feeding period is probably insufficient, according to Marc.
Very too early infants have higher levels of DHA - an omega-3 fatty acid that's basic to the improvement and development of the brain - when their breast-feeding mothers believe DHA supplements, Canadian researchers have found. Researchers say a deficiency in DHA (docosahexaenoic acid) is common in very preterm infants, possibly because the ordinary diets of many in the or breast-feeding women lack the essential fatty acid, which is found in cold water fatty fish and fish lubricator supplements.
The study included breast-feeding mothers of 12 infants born at 29 weeks gestation or earlier. The mothers were given high-priced doses of DHA supplements until 36 weeks after conception. The mothers and babies in this intervention series were compared at date 49 to a control group of mothers of very preterm infants who didn't take DHA supplements.
The levels of DHA in the knocker milk of mothers who took DHA supplements were nearly 12 times higher than in the draw off of mothers in the control group. Infants in the intervention group received about seven times more DHA than those in the hold back group. Plasma DHA concentrations in mothers and babies in the intervention league were two to three times higher than those in the control group.
So "Our study has shown that supplementing mothers is a usable and effective way of providing DHA to low birthweight premature infants," review author Dr Isabelle Marc, an assistant professor in the pediatrics department at Laval University in Quebec, said in a item release. The DHA content in the breast drain of mothers who don't consume fish during the breast-feeding period is probably insufficient, according to Marc.
Thursday 26 December 2019
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer.
Combinations of targeted therapies for an especially martial strain of breast cancer could potentially usher the best part of affected patients into remission, researchers at a major breast cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to use HER2-positive tumors resulted in much higher forgiveness rates than doses of any one treat or standard chemotherapy alone. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is quick to a protein called sympathetic epidermal expansion factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically quarry HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven efficacious on these types of tumors, which tend to be more aggressive than other breast cancers. "I think it's a very rousing era, because we've gone from a very lethal era - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of prescription at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with originally core cancer at 85 facilities throughout Germany. About half of these patients achieved deliverance before surgery, said Dr Michael Untch, head of the multidisciplinary breast cancer sphere of influence at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy".
The rig will continue following the patients to see if remission at surgery affects their outcome. Another cram showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Combinations of targeted therapies for an especially martial strain of breast cancer could potentially usher the best part of affected patients into remission, researchers at a major breast cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to use HER2-positive tumors resulted in much higher forgiveness rates than doses of any one treat or standard chemotherapy alone. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is quick to a protein called sympathetic epidermal expansion factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically quarry HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven efficacious on these types of tumors, which tend to be more aggressive than other breast cancers. "I think it's a very rousing era, because we've gone from a very lethal era - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of prescription at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with originally core cancer at 85 facilities throughout Germany. About half of these patients achieved deliverance before surgery, said Dr Michael Untch, head of the multidisciplinary breast cancer sphere of influence at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy".
The rig will continue following the patients to see if remission at surgery affects their outcome. Another cram showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Annually Mammography For Older Women Significantly Reduces The Likelihood That It Would Be Necessary Mastectomy
Annually Mammography For Older Women Significantly Reduces The Likelihood That It Would Be Necessary Mastectomy.
Yearly mammograms for women between the ages of 40 and 50 dramatically truncate the unpremeditated that a mastectomy will be high-priority if they develop breast cancer, a original study suggests. British researchers studied the records of 156 women in that grow old range who had been diagnosed with breast cancer between 2003 and 2009, and treated at the London Breast Institute. Of these women, 114 had never had a mammogram and 42 had had at least one mammogram within the terminal two years, including 16 who had had a mammogram within one year.
About 19 percent of the women who'd been screened within one year had a mastectomy, the over found, compared with 46 percent of those who had not had a mammogram the early year. Because annual mammograms allowed tumors to be discovered earlier, breast-sparing surgery was reachable for most of the women, said Dr Nicholas M Perry, the study's take the lead author. Perry, governor of the institute, at the Princess Grace Hospital in London, was to present the study findings Wednesday in Chicago at the annual converging of the Radiological Society of North America.
And "You're talking about lowering the billion of mastectomies by 30 percent. That's 2000 mastectomies in the UK every year, and in the US, that's over 10000 mastectomies saved in a year. The numbers are big and impressive, and tit cancer in minor women is a very big issue". Among all women diagnosed with breast cancer at the London institute during the bookwork period, 40 percent were younger than 50.
According to the American Cancer Society, about 207000 immature cases of invasive breast cancer will be diagnosed in women in the United States this year. The group recommends annual mammograms for women 40 and older, but a report in November 2009 from the US Preventive Services Task Force suggested that screenings begin at ripen 50 and be given every other year.
Yearly mammograms for women between the ages of 40 and 50 dramatically truncate the unpremeditated that a mastectomy will be high-priority if they develop breast cancer, a original study suggests. British researchers studied the records of 156 women in that grow old range who had been diagnosed with breast cancer between 2003 and 2009, and treated at the London Breast Institute. Of these women, 114 had never had a mammogram and 42 had had at least one mammogram within the terminal two years, including 16 who had had a mammogram within one year.
About 19 percent of the women who'd been screened within one year had a mastectomy, the over found, compared with 46 percent of those who had not had a mammogram the early year. Because annual mammograms allowed tumors to be discovered earlier, breast-sparing surgery was reachable for most of the women, said Dr Nicholas M Perry, the study's take the lead author. Perry, governor of the institute, at the Princess Grace Hospital in London, was to present the study findings Wednesday in Chicago at the annual converging of the Radiological Society of North America.
And "You're talking about lowering the billion of mastectomies by 30 percent. That's 2000 mastectomies in the UK every year, and in the US, that's over 10000 mastectomies saved in a year. The numbers are big and impressive, and tit cancer in minor women is a very big issue". Among all women diagnosed with breast cancer at the London institute during the bookwork period, 40 percent were younger than 50.
According to the American Cancer Society, about 207000 immature cases of invasive breast cancer will be diagnosed in women in the United States this year. The group recommends annual mammograms for women 40 and older, but a report in November 2009 from the US Preventive Services Task Force suggested that screenings begin at ripen 50 and be given every other year.
Monday 23 December 2019
Sports Prevents Breast Cancer
Sports Prevents Breast Cancer.
Vigorous make nervous on a regular basis might lend a hand protect black women against an aggressive form of breast cancer, researchers have found in Dec 2013. The unusual study included nearly 45000 black women, aged 30 and older, who were followed for nearly 20 years. Those who affianced in vigorous exercise for a lifetime average of three or more hours a week were 47 percent less in all probability to develop so-called estrogen receptor-negative breast cancer compared with those who exercised an common of one hour per week, the investigators found.
This type of bust cancer, which includes HER2-positive and triple-negative tumors, is linked to both higher incidence and death jeopardize in black women, compared to white women. These estrogen receptor-negative tumors do not return to the types of hormone therapies used to treat tumors that have the estrogen receptor, the researchers said in a Georgetown University Medical Center report release.
Vigorous make nervous on a regular basis might lend a hand protect black women against an aggressive form of breast cancer, researchers have found in Dec 2013. The unusual study included nearly 45000 black women, aged 30 and older, who were followed for nearly 20 years. Those who affianced in vigorous exercise for a lifetime average of three or more hours a week were 47 percent less in all probability to develop so-called estrogen receptor-negative breast cancer compared with those who exercised an common of one hour per week, the investigators found.
This type of bust cancer, which includes HER2-positive and triple-negative tumors, is linked to both higher incidence and death jeopardize in black women, compared to white women. These estrogen receptor-negative tumors do not return to the types of hormone therapies used to treat tumors that have the estrogen receptor, the researchers said in a Georgetown University Medical Center report release.
Saturday 21 December 2019
Efficiency Of Breast-Feeding On Brain Activity Of The Baby
Efficiency Of Breast-Feeding On Brain Activity Of The Baby.
Breast-feeding is excellent for a baby's brain, a unexplored study says in June 2013. Researchers employed MRI scans to examine brain growth in 133 children ranging in ripen from 10 months to 4 years. By age 2, babies who were breast-fed exclusively for at least three months had greater levels of occurrence in key parts of the brain than those who were fed formulary only or a combination of formula and breast milk. The extra growth was most evident in parts of the knowledge associated with things such as language, emotional function and thinking skills, according to the study published online May 28 in the register NeuroImage.
So "We're finding the difference in white question growth is on the order of 20 to 30 percent, comparing the breast-fed and the non-breast-fed kids," consider author Sean Deoni, an assistant professor of engineering at Brown University, said in a university communication release. "I think it's astounding that you could have that much difference so early".
Breast-feeding is excellent for a baby's brain, a unexplored study says in June 2013. Researchers employed MRI scans to examine brain growth in 133 children ranging in ripen from 10 months to 4 years. By age 2, babies who were breast-fed exclusively for at least three months had greater levels of occurrence in key parts of the brain than those who were fed formulary only or a combination of formula and breast milk. The extra growth was most evident in parts of the knowledge associated with things such as language, emotional function and thinking skills, according to the study published online May 28 in the register NeuroImage.
So "We're finding the difference in white question growth is on the order of 20 to 30 percent, comparing the breast-fed and the non-breast-fed kids," consider author Sean Deoni, an assistant professor of engineering at Brown University, said in a university communication release. "I think it's astounding that you could have that much difference so early".
Sunday 15 December 2019
Early Mammography For Women Younger Than 50 Years With A Moderate History
Early Mammography For Women Younger Than 50 Years With A Moderate History.
Mammograms given to women under 50 with a middle-of-the-road classification history of knocker cancer can spot cancers earlier and increase the odds for long-term survival, a new ponder shows. British researchers examined mammogram results for 6,710 women with several relatives with titty cancer, or at least one relative diagnosed before age 40, finding that 136 were diagnosed with the malignancy between 2003 and 2007. These women, who researchers said were perhaps not carriers of a mutated BRCA mamma cancer gene, started receiving mammograms at an earlier age than recommended by the UK National Health Service, which currently offers the screenings every three years for women between the ages of 50 and 70.
Findings showed their tumors were smaller and less martial than those in women screened at regular ages, and these women were more able to be alive 10 years after diagnosis of an invasive cancer, the researchers said. "We were not root and branch surprised at the findings," said lead researcher Stephen Duffy, a professor of cancer screening at Barts and The London School of Medicine and Dentistry at Queen Mary University of London.
And "There is already reveal that natives screening with mammography works in women under 50, even if it is more less effective than at later ages. However, there is evidence that women with a family history have denser tit tissue, which makes mammography a tougher job, so we were not sure what to expect. We did not explicitly remove BRCA-positive women but very few with an identified mutation were recruits, and because the women had a moderate rather than an extensive family history, we fancy there were very few cases among the vast majority who had not been tested for mutations".
Duffy juxtaposed his findings against the in the air debate among US public health experts, who disagree over whether annual mammograms are vital beginning at the age of 40, which has been the standard for years. In November 2009, the US Preventive Services Task Force sparked desecrate when it revised its mammogram recommendations, suggesting that screenings can be delayed until age 50 and be given every other year.
And "There are two issues here. The first is that there is some documentation of a mortality benefit of screening women in their 40s, albeit a lesser one than in older women. The assistant is that our study does not relate to population screening, but to mammographic surveillance of women who are concerned about their kin history of breast or ovarian cancer".
Mammograms given to women under 50 with a middle-of-the-road classification history of knocker cancer can spot cancers earlier and increase the odds for long-term survival, a new ponder shows. British researchers examined mammogram results for 6,710 women with several relatives with titty cancer, or at least one relative diagnosed before age 40, finding that 136 were diagnosed with the malignancy between 2003 and 2007. These women, who researchers said were perhaps not carriers of a mutated BRCA mamma cancer gene, started receiving mammograms at an earlier age than recommended by the UK National Health Service, which currently offers the screenings every three years for women between the ages of 50 and 70.
Findings showed their tumors were smaller and less martial than those in women screened at regular ages, and these women were more able to be alive 10 years after diagnosis of an invasive cancer, the researchers said. "We were not root and branch surprised at the findings," said lead researcher Stephen Duffy, a professor of cancer screening at Barts and The London School of Medicine and Dentistry at Queen Mary University of London.
And "There is already reveal that natives screening with mammography works in women under 50, even if it is more less effective than at later ages. However, there is evidence that women with a family history have denser tit tissue, which makes mammography a tougher job, so we were not sure what to expect. We did not explicitly remove BRCA-positive women but very few with an identified mutation were recruits, and because the women had a moderate rather than an extensive family history, we fancy there were very few cases among the vast majority who had not been tested for mutations".
Duffy juxtaposed his findings against the in the air debate among US public health experts, who disagree over whether annual mammograms are vital beginning at the age of 40, which has been the standard for years. In November 2009, the US Preventive Services Task Force sparked desecrate when it revised its mammogram recommendations, suggesting that screenings can be delayed until age 50 and be given every other year.
And "There are two issues here. The first is that there is some documentation of a mortality benefit of screening women in their 40s, albeit a lesser one than in older women. The assistant is that our study does not relate to population screening, but to mammographic surveillance of women who are concerned about their kin history of breast or ovarian cancer".
Monday 9 December 2019
Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer
Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer.
In an trouble to pick up the prognosis of patients battling triple-negative breast cancer, scientists have identified a solitary biomarker that may eventually allow some to receive a more targeted treatment. Although less uncommon, triple negative breast cancer is notoriously difficult to treat because receptor targeted therapies don't work.
The disease's honour refers to breast cancers that analysis negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2(HER2), all of which fossil most breast cancer growth. "Triple-negative breast cancers currently require therapeutic targets and are managed with conventional chemotherapy," study author Dr Agnieszka K Witkiewicz, an fellow professor of pathology at Thomas Jefferson University Hospital in Philadelphia, explained in a report release.
In an trouble to pick up the prognosis of patients battling triple-negative breast cancer, scientists have identified a solitary biomarker that may eventually allow some to receive a more targeted treatment. Although less uncommon, triple negative breast cancer is notoriously difficult to treat because receptor targeted therapies don't work.
The disease's honour refers to breast cancers that analysis negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2(HER2), all of which fossil most breast cancer growth. "Triple-negative breast cancers currently require therapeutic targets and are managed with conventional chemotherapy," study author Dr Agnieszka K Witkiewicz, an fellow professor of pathology at Thomas Jefferson University Hospital in Philadelphia, explained in a report release.
Sunday 1 December 2019
Node Negative Breast Cancer Is Better Treated By Chemotherapy
Node Negative Breast Cancer Is Better Treated By Chemotherapy.
A chemotherapy regimen already proven higher-level to other regimens for teat cancer that has spread to the lymph nodes may also plough better for some women whose cancers haven't spread, a new study has found. When it came to these "node-negative" cancers, the numb combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the trust of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said. The TAC regimen was better at keeping women swarming and disease-free after a median follow up of almost six and a half years, the con found.
So "For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most attractive options," said study co-author Dr Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid. The analysis was funded by the knock out maker Sanofi-Aventis - which makes Taxotere, the brand name for docetaxel - and GEICAM, the Spanish Breast Cancer Research Group. The results are published in the Dec 2, 2010 appear of the New England Journal of Medicine.
To adjudge which women with bust cancer would benefit from adjuvant chemotherapy (typically chemotherapy after surgery), doctors undertake into account a number of risk factors, such as the patient's age, tumor size and other characteristics. For the unknown study, the researchers assigned 1060 women with breast cancers that were axillary-node pessimistic who had at least one high-risk factor for recurrence to one of the two treatment regimens every three weeks for six cycles after their surgery.
At the 77-month mark, almost 88 percent of the TAC women were animated and disease-free, compared to buddy-buddy to 82 percent of the women in the FAC group. Those in the TAC aggregation had a 32 percent reduction in the risk of recurrence, the study authors said. The reduced peril held true even after taking into account a number of high-risk factors, such as age, the women's menopausal eminence and tumor characteristics.
A chemotherapy regimen already proven higher-level to other regimens for teat cancer that has spread to the lymph nodes may also plough better for some women whose cancers haven't spread, a new study has found. When it came to these "node-negative" cancers, the numb combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the trust of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said. The TAC regimen was better at keeping women swarming and disease-free after a median follow up of almost six and a half years, the con found.
So "For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most attractive options," said study co-author Dr Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid. The analysis was funded by the knock out maker Sanofi-Aventis - which makes Taxotere, the brand name for docetaxel - and GEICAM, the Spanish Breast Cancer Research Group. The results are published in the Dec 2, 2010 appear of the New England Journal of Medicine.
To adjudge which women with bust cancer would benefit from adjuvant chemotherapy (typically chemotherapy after surgery), doctors undertake into account a number of risk factors, such as the patient's age, tumor size and other characteristics. For the unknown study, the researchers assigned 1060 women with breast cancers that were axillary-node pessimistic who had at least one high-risk factor for recurrence to one of the two treatment regimens every three weeks for six cycles after their surgery.
At the 77-month mark, almost 88 percent of the TAC women were animated and disease-free, compared to buddy-buddy to 82 percent of the women in the FAC group. Those in the TAC aggregation had a 32 percent reduction in the risk of recurrence, the study authors said. The reduced peril held true even after taking into account a number of high-risk factors, such as age, the women's menopausal eminence and tumor characteristics.
Monday 22 January 2018
Doctors Recommend A New Treatment For Cancer
Doctors Recommend A New Treatment For Cancer.
The sedative Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at apex risk for the disease, according to a new study Dec 2013. The finding, scheduled for visual Thursday at the San Antonio Breast Cancer Symposium in Texas, adds look forward to that Arimidex (anastrozole) might be a valuable new preventive option for some women. The enquiry will also be published in the journal The Lancet.
So "Two other antihormone therapies, tamoxifen and raloxifene, are reach-me-down by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which hold in check their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will pre-eminence to an alternative prevention therapy with fewer ancillary effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, aim of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.
About 80 percent of US teat cancer patients have tumors with boisterous levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore employed to treat postmenopausal women with hormone receptor-positive core cancer. The study included more than 3800 postmenopausal women at increased gamble for breast cancer due to having two or more blood relatives with breast cancer, having a mummy or sister who developed breast cancer before age 50, or having a spoil or sister who had breast cancer in both breasts.
The sedative Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at apex risk for the disease, according to a new study Dec 2013. The finding, scheduled for visual Thursday at the San Antonio Breast Cancer Symposium in Texas, adds look forward to that Arimidex (anastrozole) might be a valuable new preventive option for some women. The enquiry will also be published in the journal The Lancet.
So "Two other antihormone therapies, tamoxifen and raloxifene, are reach-me-down by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which hold in check their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will pre-eminence to an alternative prevention therapy with fewer ancillary effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, aim of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.
About 80 percent of US teat cancer patients have tumors with boisterous levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore employed to treat postmenopausal women with hormone receptor-positive core cancer. The study included more than 3800 postmenopausal women at increased gamble for breast cancer due to having two or more blood relatives with breast cancer, having a mummy or sister who developed breast cancer before age 50, or having a spoil or sister who had breast cancer in both breasts.
Thursday 7 December 2017
A Used Breast Pump Can Carry Infectious Diseases
A Used Breast Pump Can Carry Infectious Diseases.
Women who are breast-feeding should take possession of precautions when deciding what category of breast pump to use, particularly if they are all in all buying or renting a used or second-hand pump, according to a new report, which was released Jan 15, 2013 from the US Food and Drug Administration. Although core pumps can range from single, vade-mecum pumps to double, electric-powered models, all have a few basic parts, including a breast defend that fits over the nipple, a pump that creates a vacuum to express the milk and a detachable container for collecting the milk, Kathryn Daws-Kopp, an FDA electrical engineer, said in the report. The FDA oversees the safe keeping and effectiveness of these devices.
Although women can corrupt breast pumps, many hospitals, medical stock stores and lactation consultants rent breast pumps that can be used by multiple women. The FDA advised all women who use rented or hand-me-down pumps to buy an accessory trappings with new breast shields and tubing - even if the existing kit looks clean. Potentially catching particles may linger in a breast pump or its accessories for a long time after a woman finishes using it.
These germs can infect the babe in arms or the next woman who uses that pump, said Dr Michael Cummings, an obstetrician and gynecologist with the FDA. The report, published on the Consumer Updates summon of the FDA's website, offers the following tips to insure that a breast pump is clean. Rinse each subordinate that comes into contact with breast milk in cool water immediately after pumping.
Wash each accessory independently using liquid dishwashing soap and warm water, and rinse each piece in hot water for 10 to 15 seconds. Allow each adventitious to air-dry completely on a clean towel or drying rack. The FDA popular that women who rent breast pumps should request that all parts of their push be cleaned, disinfected and sterilized according to the manufacturer's directions.
Women who are breast-feeding should take possession of precautions when deciding what category of breast pump to use, particularly if they are all in all buying or renting a used or second-hand pump, according to a new report, which was released Jan 15, 2013 from the US Food and Drug Administration. Although core pumps can range from single, vade-mecum pumps to double, electric-powered models, all have a few basic parts, including a breast defend that fits over the nipple, a pump that creates a vacuum to express the milk and a detachable container for collecting the milk, Kathryn Daws-Kopp, an FDA electrical engineer, said in the report. The FDA oversees the safe keeping and effectiveness of these devices.
Although women can corrupt breast pumps, many hospitals, medical stock stores and lactation consultants rent breast pumps that can be used by multiple women. The FDA advised all women who use rented or hand-me-down pumps to buy an accessory trappings with new breast shields and tubing - even if the existing kit looks clean. Potentially catching particles may linger in a breast pump or its accessories for a long time after a woman finishes using it.
These germs can infect the babe in arms or the next woman who uses that pump, said Dr Michael Cummings, an obstetrician and gynecologist with the FDA. The report, published on the Consumer Updates summon of the FDA's website, offers the following tips to insure that a breast pump is clean. Rinse each subordinate that comes into contact with breast milk in cool water immediately after pumping.
Wash each accessory independently using liquid dishwashing soap and warm water, and rinse each piece in hot water for 10 to 15 seconds. Allow each adventitious to air-dry completely on a clean towel or drying rack. The FDA popular that women who rent breast pumps should request that all parts of their push be cleaned, disinfected and sterilized according to the manufacturer's directions.
Friday 7 July 2017
Lifestyle Affects Breast Cancer Risk
Lifestyle Affects Breast Cancer Risk.
Lifestyle changes such as losing weight, drinking less juice and getting more execute could lead to a substantial reduction in breast cancer cases across an continuous population, according to a new model that estimates the impact of these modifiable risk factors. Although such models are often occupied to estimate breast cancer risk, they are usually based on things that women can't change, such as a division history of breast cancer. Up to now, there have been few models based on ways women could cut their risk through changes in their lifestyle.
US National Cancer Institute researchers created the ideal using data from an Italian study that included more than 5000 women. The epitome included three modifiable risk factors (alcohol consumption, physical activity and body hoard index) and five risk factors that are difficult or impossible to modify: family history, education, drudgery activity, reproductive characteristics, and biopsy history. Benchmarks for some lifestyle factors included getting at least 2 hours of annoy a week for women 30-39 and having a body mass indicator (BMI) under 25 in women 50 and older.
Lifestyle changes such as losing weight, drinking less juice and getting more execute could lead to a substantial reduction in breast cancer cases across an continuous population, according to a new model that estimates the impact of these modifiable risk factors. Although such models are often occupied to estimate breast cancer risk, they are usually based on things that women can't change, such as a division history of breast cancer. Up to now, there have been few models based on ways women could cut their risk through changes in their lifestyle.
US National Cancer Institute researchers created the ideal using data from an Italian study that included more than 5000 women. The epitome included three modifiable risk factors (alcohol consumption, physical activity and body hoard index) and five risk factors that are difficult or impossible to modify: family history, education, drudgery activity, reproductive characteristics, and biopsy history. Benchmarks for some lifestyle factors included getting at least 2 hours of annoy a week for women 30-39 and having a body mass indicator (BMI) under 25 in women 50 and older.
Monday 5 June 2017
Mammography Should Be Done On Time
Mammography Should Be Done On Time.
Breast cancer patients who have mammograms every 12 to 18 months have less endanger of lymph node involvement than those who hiatus longer, therefore improving their outlook, according to an prehistoric new study. As breast cancer progresses, cancer cells may vastness to the lymph nodes and other parts of the body, requiring more extensive treatment. "We found doing mammograms at intervals longer than one and a half years essentially does fake patient prognosis," said examine researcher Dr Lilian Wang.
And "In our study, those patients were found to have a significantly greater lymph node positivity". From 2007 to 2010, Wang evaluated more than 300 women, all of whom were diagnosed with bust cancer found during a boring mammogram. She divided them into three groups, based on the meantime between mammograms: less than one and a half years, one and a half to three years or more than three years.
Most women were in the blue ribbon category. Wang looked to see how many women had cancer that had spread to their lymph nodes. Although nearly 9 percent of those in the shortest time had lymph node involvement, 21 percent of those in the medial group and more than 15 percent in the longest-interval group did. The stage at which the cancer was diagnosed did not different among the groups, she found.
Although the study found an association between more frequent screenings and less lymph node involvement amidst breast cancer patients, it did not establish a cause-and-effect relationship. Wang, an aid professor of radiology at Northwestern University's Feinberg School of Medicine, is scheduled to present the findings Wednesday at the annual rendezvous of the Radiological Society of North America, in Chicago. The best void between routine mammograms has been a point of discussion and debate for years.
Breast cancer patients who have mammograms every 12 to 18 months have less endanger of lymph node involvement than those who hiatus longer, therefore improving their outlook, according to an prehistoric new study. As breast cancer progresses, cancer cells may vastness to the lymph nodes and other parts of the body, requiring more extensive treatment. "We found doing mammograms at intervals longer than one and a half years essentially does fake patient prognosis," said examine researcher Dr Lilian Wang.
And "In our study, those patients were found to have a significantly greater lymph node positivity". From 2007 to 2010, Wang evaluated more than 300 women, all of whom were diagnosed with bust cancer found during a boring mammogram. She divided them into three groups, based on the meantime between mammograms: less than one and a half years, one and a half to three years or more than three years.
Most women were in the blue ribbon category. Wang looked to see how many women had cancer that had spread to their lymph nodes. Although nearly 9 percent of those in the shortest time had lymph node involvement, 21 percent of those in the medial group and more than 15 percent in the longest-interval group did. The stage at which the cancer was diagnosed did not different among the groups, she found.
Although the study found an association between more frequent screenings and less lymph node involvement amidst breast cancer patients, it did not establish a cause-and-effect relationship. Wang, an aid professor of radiology at Northwestern University's Feinberg School of Medicine, is scheduled to present the findings Wednesday at the annual rendezvous of the Radiological Society of North America, in Chicago. The best void between routine mammograms has been a point of discussion and debate for years.
Tuesday 23 May 2017
Mammogram Warns Against Cancer
Mammogram Warns Against Cancer.
Often-conflicting results from studies on the value of procedure mammography have only fueled the argument about how often women should get a mammogram and at what age they should start. In a new examination of previous research, experts have applied the same statistical yardstick to four large studies and re-examined the results. They found that the benefits are more in conformance across the large studies than previously thought. All the studies showed a affluent reduction in breast cancer deaths with mammography screening.
So "Women should be reassured that mammography is completely effective," said study researcher Robert Smith, senior manager of cancer screening for the American Cancer Society. Smith is scheduled to present the findings this week at the 2013 San Antonio Breast Cancer Symposium. The findings also were published in the November distribution of the weekly Breast Cancer Management.
In 2009, the US Preventive Services Task Force (USPSTF), an self-assured group of national experts, updated its recommendation on mammography, advising women elderly 50 to 74 to get mammograms every two years, not annually.The group also advised women venerable 40 to 49 to talk to their doctors about benefits and harms, and decide on an lone basis whether to start screening. Other organizations, including the American Cancer Society, on to recommend annual screening mammograms beginning at age 40.
In assessing mammography's benefits and harms, researchers often demeanour at the number of women who must be screened to prevent one death from breast cancer - a issue that has ranged widely among studies. In assessing harms, experts defraud into account the possibility of false positives. Other possible harms include finding a cancer that would not otherwise have been found on screening (and not been questionable in a woman's lifetime) and anxiety associated with additional testing.
Often-conflicting results from studies on the value of procedure mammography have only fueled the argument about how often women should get a mammogram and at what age they should start. In a new examination of previous research, experts have applied the same statistical yardstick to four large studies and re-examined the results. They found that the benefits are more in conformance across the large studies than previously thought. All the studies showed a affluent reduction in breast cancer deaths with mammography screening.
So "Women should be reassured that mammography is completely effective," said study researcher Robert Smith, senior manager of cancer screening for the American Cancer Society. Smith is scheduled to present the findings this week at the 2013 San Antonio Breast Cancer Symposium. The findings also were published in the November distribution of the weekly Breast Cancer Management.
In 2009, the US Preventive Services Task Force (USPSTF), an self-assured group of national experts, updated its recommendation on mammography, advising women elderly 50 to 74 to get mammograms every two years, not annually.The group also advised women venerable 40 to 49 to talk to their doctors about benefits and harms, and decide on an lone basis whether to start screening. Other organizations, including the American Cancer Society, on to recommend annual screening mammograms beginning at age 40.
In assessing mammography's benefits and harms, researchers often demeanour at the number of women who must be screened to prevent one death from breast cancer - a issue that has ranged widely among studies. In assessing harms, experts defraud into account the possibility of false positives. Other possible harms include finding a cancer that would not otherwise have been found on screening (and not been questionable in a woman's lifetime) and anxiety associated with additional testing.
Monday 22 May 2017
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a conclusion that seems to token the prevailing wisdom that any form of hormone replacement cure raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone group therapy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone treatment is actually protective" in women who have a low risk for developing heart tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another glance at text from the Women's Health Initiative (WHI) study, a nationalistic trial that has focused on ways to prevent breast and colorectal cancer, as well as guts disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, unequal studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were part of the trial run - women who had had hysterectomies and took estrogen unassisted as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The confederation therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no ex history of benign heart of hearts disease had a 43 percent reduction breast cancer risk on estrogen; women with no kinsfolk history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without foregoing hormone use had a 32 percent reduced risk.
In a conclusion that seems to token the prevailing wisdom that any form of hormone replacement cure raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone group therapy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone treatment is actually protective" in women who have a low risk for developing heart tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another glance at text from the Women's Health Initiative (WHI) study, a nationalistic trial that has focused on ways to prevent breast and colorectal cancer, as well as guts disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, unequal studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were part of the trial run - women who had had hysterectomies and took estrogen unassisted as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The confederation therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no ex history of benign heart of hearts disease had a 43 percent reduction breast cancer risk on estrogen; women with no kinsfolk history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without foregoing hormone use had a 32 percent reduced risk.
Thursday 4 May 2017
Extract Of Bitter Melon May Slow Breast Cancer
Extract Of Bitter Melon May Slow Breast Cancer.
A accepted nutritional extend - extract of bitter melon - may help preserve women from breast cancer, researchers say. Bitter melon is a common vegetable in India, China and South America, and its wrench is used in folk remedies for diabetes because of its blood-sugar lowering capabilities, according to the researchers. "When we employed the extract from that melon, we saw that it kills the breast cancer cells," said main researcher Ratna Ray, a professor of pathology at Saint Louis University. But their toil was done in a laboratory, not in humans.
The bitter melon extract killed only the cancer cells, not the salutary breast cells. "We didn't see any death in the normal cells". However, these results are not ammunition that bitter melon extract prevents or cures breast cancer. "I don't accept that it will cure cancer. It will probably delay or perhaps have some prevention."
The disclose was published online Feb 23 in advance of print publication March 1 in Cancer Research. For the study, Ray's duo treated human breast cancer cells with distressful melon extract, which is sold in US health food stores and over the Internet.
The cull slowed the growth of these breast cancer cells and even killed them, the researchers found. The next out of step is to see if the team can repeat these findings in animals. If so, considerate trials might follow.
A accepted nutritional extend - extract of bitter melon - may help preserve women from breast cancer, researchers say. Bitter melon is a common vegetable in India, China and South America, and its wrench is used in folk remedies for diabetes because of its blood-sugar lowering capabilities, according to the researchers. "When we employed the extract from that melon, we saw that it kills the breast cancer cells," said main researcher Ratna Ray, a professor of pathology at Saint Louis University. But their toil was done in a laboratory, not in humans.
The bitter melon extract killed only the cancer cells, not the salutary breast cells. "We didn't see any death in the normal cells". However, these results are not ammunition that bitter melon extract prevents or cures breast cancer. "I don't accept that it will cure cancer. It will probably delay or perhaps have some prevention."
The disclose was published online Feb 23 in advance of print publication March 1 in Cancer Research. For the study, Ray's duo treated human breast cancer cells with distressful melon extract, which is sold in US health food stores and over the Internet.
The cull slowed the growth of these breast cancer cells and even killed them, the researchers found. The next out of step is to see if the team can repeat these findings in animals. If so, considerate trials might follow.
Wednesday 8 March 2017
An Effect Of Hormone Therapy On Breast Cancer
An Effect Of Hormone Therapy On Breast Cancer.
Although several overweight studies in latest years have linked the use of hormone therapy after menopause with an increased danger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another air at three eminently studies that investigated hormone therapy and its credible health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased jeopardize of breast cancer centre of women who used the combination form of hormone therapy with both estrogen and progesterone.
Women who have had a hysterectomy and use estrogen-only group therapy also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only remedy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI scrutinize was published in July 2002, women dropped hormone cure in droves.
Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The declivity in breast cancer extent started three years before the fall in HRT use commenced, lasted for only one year after the HRT dab commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the numeral of new breast cancer cases fell by nearly 7 percent.
In taking a bearing at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria superior to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The fact is not strong enough to say definitively that hormone therapy causes breast cancer. The go into is published in the current issue of the Journal of Family Planning and Reproductive Health Care.
Although several overweight studies in latest years have linked the use of hormone therapy after menopause with an increased danger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another air at three eminently studies that investigated hormone therapy and its credible health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased jeopardize of breast cancer centre of women who used the combination form of hormone therapy with both estrogen and progesterone.
Women who have had a hysterectomy and use estrogen-only group therapy also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only remedy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI scrutinize was published in July 2002, women dropped hormone cure in droves.
Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The declivity in breast cancer extent started three years before the fall in HRT use commenced, lasted for only one year after the HRT dab commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the numeral of new breast cancer cases fell by nearly 7 percent.
In taking a bearing at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria superior to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The fact is not strong enough to say definitively that hormone therapy causes breast cancer. The go into is published in the current issue of the Journal of Family Planning and Reproductive Health Care.
Saturday 4 February 2017
Doctors Recommend A New Complex Cancer Treatment
Doctors Recommend A New Complex Cancer Treatment.
Women with assertive chest cancer who receive combination targeted therapy with chemotherapy prior to surgery have a measure improved chance of staying cancer-free, researchers say. However, the improvement was not statistically significant and the jury is still out on league treatment, said lead researcher Dr Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels. "I don't judge that tomorrow we should switch to a new classic of care.
Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other scrutinize that investigated ways to improve treatment for women with HER2-positive breast cancer. This bellicose form of cancer is linked to a genetic irregularity. Other researchers reported the following. The targeted anaesthetize trastuzumab (Herceptin) worked better in HER2-positive breast cancer tumors containing exhilarated levels of immune cells.
A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery care option. Overall, the studies were good low-down for women with HER2-positive breast cancer, which used to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted psychoanalysis drugs. "That tells you these treatments are very, very effective," Piccart-Gebhart said.
Piccart-Gebhart's combo targeted analysis suffering is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) work better when combined on first of standard chemotherapy. The trial involved 455 patients with HER2-positive tit cancer with tumors larger than 2 centimeters. The women were given chemotherapy prior to surgery along with either Herceptin, Tykerb, or a set of the two targeted drugs. They also were treated after surgery with whichever targeted remedy they had been receiving.
Piccart-Gebhart reported that 84 percent of the patients who received the combination targeted psychotherapy between 2008 and 2010 have remained cancer-free, compared with 76 percent who only received Herceptin. "It's too inopportune today to say this dual treatment saves more lives. We can't opportunity that on the basis of this trial". The drawbacks of this combination therapy are cost and side effects, Piccart-Gebhart said.
Women with assertive chest cancer who receive combination targeted therapy with chemotherapy prior to surgery have a measure improved chance of staying cancer-free, researchers say. However, the improvement was not statistically significant and the jury is still out on league treatment, said lead researcher Dr Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels. "I don't judge that tomorrow we should switch to a new classic of care.
Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other scrutinize that investigated ways to improve treatment for women with HER2-positive breast cancer. This bellicose form of cancer is linked to a genetic irregularity. Other researchers reported the following. The targeted anaesthetize trastuzumab (Herceptin) worked better in HER2-positive breast cancer tumors containing exhilarated levels of immune cells.
A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery care option. Overall, the studies were good low-down for women with HER2-positive breast cancer, which used to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted psychoanalysis drugs. "That tells you these treatments are very, very effective," Piccart-Gebhart said.
Piccart-Gebhart's combo targeted analysis suffering is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) work better when combined on first of standard chemotherapy. The trial involved 455 patients with HER2-positive tit cancer with tumors larger than 2 centimeters. The women were given chemotherapy prior to surgery along with either Herceptin, Tykerb, or a set of the two targeted drugs. They also were treated after surgery with whichever targeted remedy they had been receiving.
Piccart-Gebhart reported that 84 percent of the patients who received the combination targeted psychotherapy between 2008 and 2010 have remained cancer-free, compared with 76 percent who only received Herceptin. "It's too inopportune today to say this dual treatment saves more lives. We can't opportunity that on the basis of this trial". The drawbacks of this combination therapy are cost and side effects, Piccart-Gebhart said.
Sunday 22 January 2017
New Methods In The Study Of Breast Cancer
New Methods In The Study Of Breast Cancer.
An exploratory blood try could help show whether women with advanced breast cancer are responding to treatment, a preparation study suggests. The test detects abnormal DNA from tumor cells circulating in the blood. And the unique findings, reported in the March 14 issue of the New England Journal of Medicine, implication that it could outperform existing blood tests at gauging some women's answer to treatment for metastatic breast cancer. That's an advanced form of breast cancer, where tumors have bounds to other parts of the body - most often the bones, lungs, liver or brain.
There is no cure, but chemotherapy, hormonal group therapy or other treatments can slow disease progression and ease symptoms. The sooner doctors can recount whether the treatment is working, the better. That helps women avoid the school effects of an ineffective therapy, and may enable them to switch to a better one.
Right now, doctors monitor metastatic heart of hearts cancer with the help of imaging tests, such as CT scans. They may also use certain blood tests - including one that detects tumor cells floating in the bloodstream, and one that measures a tumor "marker" called CA 15-3.
But imaging does not discriminate the sound story, and it can expose women to significant doses of radiation. The blood tests also have limitations and are not routinely used. "Practically speaking, there's a whopping prerequisite for novel methods" of monitoring women, said Dr Yuan Yuan, an aid professor of medical oncology at City of Hope cancer center in Duarte, Calif.
For the untrained study, researchers at the University of Cambridge in England took blood samples from 30 women being treated for metastatic teat cancer and having standard imaging tests. They found that the tumor DNA check performed better than either the CA 15-3 or the tumor cell prove when it came to estimating the women's treatment response. Of 20 women the researchers were able to follow for more than 100 days, 19 showed cancer chain on their CT scans.
And 17 of them had shown rising tumor DNA levels. In contrast, only seven had a rising handful of tumor cells, while nine had an increase in CA 15-3 levels. For 10 of those 19 women, tumor DNA was on the go up an general of five months before CT scans showed their cancer was progressing. "The take-home message is that circulating tumor DNA is a better monitoring biomarker than the existing Food and Drug Administration-approved ones," said elder researcher Dr Carlos Caldas.
An exploratory blood try could help show whether women with advanced breast cancer are responding to treatment, a preparation study suggests. The test detects abnormal DNA from tumor cells circulating in the blood. And the unique findings, reported in the March 14 issue of the New England Journal of Medicine, implication that it could outperform existing blood tests at gauging some women's answer to treatment for metastatic breast cancer. That's an advanced form of breast cancer, where tumors have bounds to other parts of the body - most often the bones, lungs, liver or brain.
There is no cure, but chemotherapy, hormonal group therapy or other treatments can slow disease progression and ease symptoms. The sooner doctors can recount whether the treatment is working, the better. That helps women avoid the school effects of an ineffective therapy, and may enable them to switch to a better one.
Right now, doctors monitor metastatic heart of hearts cancer with the help of imaging tests, such as CT scans. They may also use certain blood tests - including one that detects tumor cells floating in the bloodstream, and one that measures a tumor "marker" called CA 15-3.
But imaging does not discriminate the sound story, and it can expose women to significant doses of radiation. The blood tests also have limitations and are not routinely used. "Practically speaking, there's a whopping prerequisite for novel methods" of monitoring women, said Dr Yuan Yuan, an aid professor of medical oncology at City of Hope cancer center in Duarte, Calif.
For the untrained study, researchers at the University of Cambridge in England took blood samples from 30 women being treated for metastatic teat cancer and having standard imaging tests. They found that the tumor DNA check performed better than either the CA 15-3 or the tumor cell prove when it came to estimating the women's treatment response. Of 20 women the researchers were able to follow for more than 100 days, 19 showed cancer chain on their CT scans.
And 17 of them had shown rising tumor DNA levels. In contrast, only seven had a rising handful of tumor cells, while nine had an increase in CA 15-3 levels. For 10 of those 19 women, tumor DNA was on the go up an general of five months before CT scans showed their cancer was progressing. "The take-home message is that circulating tumor DNA is a better monitoring biomarker than the existing Food and Drug Administration-approved ones," said elder researcher Dr Carlos Caldas.
Sunday 14 August 2016
Doctors Advise How To Avoid Breast Cancer
Doctors Advise How To Avoid Breast Cancer.
If a bride develops mamma cancer, having larger breasts and being sedentary might increase her risk of on one's deathbed from the disease, a large, long-term study suggests. Experts have long known that being physically effectual reduces the risk of getting breast cancer by about 25 percent. The new study, however, looked at how both drive crazy and breast size might predict survival if breast cancer does develop, said reflect on researcher Paul Williams, a staff scientist at the Lawrence Berkeley National Laboratory, in Berkeley, California Williams found a rudely 40 percent reduced risk of dying from bust cancer in physically active women compared to those who didn't meet exercise guidelines.
The retreat was published online Dec 9, 2013 in the journal PLoS One. For the study, Williams and his rig followed nearly 80000 women for 11 years. All were participants in national studies on runners' and walkers' health. About 33000 of the women were walkers and about 46000 were runners. When they entered the study, none of the women had been diagnosed with core cancer.
All reported the distances they walked or ran each week, as well as their bra cup hugeness and body charge and height. During the 11-year follow-up period, 111 examination participants died from breast cancer. They were in their mid-50s, on average, when they died. Those who met around exercise guidelines were about 42 percent less likely to die of breast cancer compared to those who did not pay the guidelines.
These guidelines recommend two and a half hours of moderate activity, an hour and 15 minutes of active activity or an equivalent combination weekly. The total of exercise found to be protective against breast cancer was about seven miles of brisk walking or nearly five miles of event each week. "It's not a lot of exercise. "This is more evidence of yet another benefit of exercise.
If a bride develops mamma cancer, having larger breasts and being sedentary might increase her risk of on one's deathbed from the disease, a large, long-term study suggests. Experts have long known that being physically effectual reduces the risk of getting breast cancer by about 25 percent. The new study, however, looked at how both drive crazy and breast size might predict survival if breast cancer does develop, said reflect on researcher Paul Williams, a staff scientist at the Lawrence Berkeley National Laboratory, in Berkeley, California Williams found a rudely 40 percent reduced risk of dying from bust cancer in physically active women compared to those who didn't meet exercise guidelines.
The retreat was published online Dec 9, 2013 in the journal PLoS One. For the study, Williams and his rig followed nearly 80000 women for 11 years. All were participants in national studies on runners' and walkers' health. About 33000 of the women were walkers and about 46000 were runners. When they entered the study, none of the women had been diagnosed with core cancer.
All reported the distances they walked or ran each week, as well as their bra cup hugeness and body charge and height. During the 11-year follow-up period, 111 examination participants died from breast cancer. They were in their mid-50s, on average, when they died. Those who met around exercise guidelines were about 42 percent less likely to die of breast cancer compared to those who did not pay the guidelines.
These guidelines recommend two and a half hours of moderate activity, an hour and 15 minutes of active activity or an equivalent combination weekly. The total of exercise found to be protective against breast cancer was about seven miles of brisk walking or nearly five miles of event each week. "It's not a lot of exercise. "This is more evidence of yet another benefit of exercise.
Subscribe to:
Posts (Atom)